Skip to content

Semaglutide studies: 1,194 papers with results

Page 7 of 24

  1. Effect of semaglutide on arrhythmic, major cardiovascular, and renal outcomes in patients with overweight or obesity: a systematic review and meta-analysis.

    Wu R · European journal of medical research · 2025

    Systematic review · 5 results

  2. Efficacy and Safety of Once-Weekly Subcutaneous Semaglutide in Overweight or Obese Adults: A Systematic Review with Meta-Analysis.

    Dorneles G · Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association · 2024

    Systematic review · 10 results

  3. Efficacy and safety of once-weekly subcutaneous semaglutide on weight loss in patients with overweight or obesity without diabetes mellitus-A systematic review and meta-analysis of randomized controlled trials.

    Kommu S · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024

    Systematic review · 12 results

  4. Semaglutide and Diabetic Retinopathy Risk in Patients with Type 2 Diabetes Mellitus: A Meta-Analysis of Randomized Controlled Trials.

    Wang F · Clinical drug investigation · 2022

    Systematic review · 5 results

  5. Suboptimal therapeutic responses associated with semaglutide in type 2 diabetes and obesity: A meta-analysis of randomized controlled trials.

    Ko D · Cell reports. Medicine · 2026

    Systematic review · 4 results

  6. Effects of subcutaneous or oral semaglutide on cardiovascular outcomes in patients with type 2 diabetes mellitus: a meta-analysis of randomized controlled trials.

    Tan S · Frontiers in cardiovascular medicine · 2025

    Systematic review · 9 results

  7. Semaglutide for adults living with obesity.

    Bracchiglione J · The Cochrane database of systematic reviews · 2025

    Systematic review · 16 results

  8. Meta-analysis of the Effect of Semaglutide on Blood Pressure in Obese Populations.

    Li Y · American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025

    Systematic review · 8 results

  9. Plastic Surgery in the Ozempidemic: Considerations for the Timing of Body Contouring Surgery in Patients with Semaglutide-Associated Weight Loss.

    Garbaccio NC · Aesthetic plastic surgery · 2025

    Systematic review · 4 results

  10. Tirzepatide Versus Semaglutide on Weight Loss in Type 2 Diabetes Patients: A Systematic Review and Meta-Analysis of Direct Comparative Studies.

    Wen J · Endocrinology, diabetes & metabolism · 2025

    Systematic review · 5 results

  11. Glucagon-like peptide-1 receptor agonist semaglutide reduces atrial fibrillation incidence: A systematic review and meta-analysis.

    Saglietto A · European journal of clinical investigation · 2024

    Systematic review · 6 results

  12. Efficacy and Safety of Once-Weekly Semaglutide for the Treatment of Type 2 Diabetes: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

    Shi FH · Frontiers in pharmacology · 2018

    Systematic review · 12 results

  13. The safety and efficacy of once-weekly glucagon-like peptide-1 receptor agonist semaglutide in patients with type 2 diabetes mellitus: a systemic review and meta-analysis.

    Li X · Endocrine · 2018

    Systematic review · 8 results

  14. Assessment of Thyroid Carcinogenic Risk and Safety Profile of GLP1-RA Semaglutide (Ozempic) Therapy for Diabetes Mellitus and Obesity: A Systematic Literature Review.

    Feier CVI · International journal of molecular sciences · 2024

    Systematic review · 12 results

  15. Assessment of noninferiority of oral vs subcutaneous semaglutide: a systematic review and meta-analysis.

    Drygalski K · Polish archives of internal medicine · 2025

    Systematic review · 6 results

  16. Effects of subcutaneous semaglutide on weight loss and inflammatory markers in adults with overweight or obesity without diabetes: a systematic review and meta-analysis.

    Milluzzo A · International journal of obesity (2005) · 2026

    Systematic review · 4 results

  17. Comparative efficacy and safety of glucagon-like peptide 1 receptor agonists for the treatment of type 2 diabetes: A network meta-analysis.

    Chen H · Medicine · 2023

    Systematic review · 6 results

  18. Efficacy and safety of subcutaneous semaglutide in adults with overweight or obese: a subgroup meta-analysis of randomized controlled trials.

    Zhang R · Frontiers in endocrinology · 2023

    Systematic review · 9 results

  19. Efficacy and safety of semaglutide in non-diabetic adults with overweight or obesity: A meta-analysis of randomized controlled trials.

    Zhang S · European journal of pharmacology · 2026

    Systematic review · 7 results

  20. Efficacy and safety of semaglutide on weight loss in obese or overweight patients without diabetes: A systematic review and meta-analysis of randomized controlled trials.

    Gao X · Frontiers in pharmacology · 2022

    Systematic review · 13 results

  21. The Effect of Semaglutide on Quality of Life in Adults With Overweight or Obesity: A Brief Systematic Review and Meta-Analysis.

    Eisa N · Diabetes, obesity & metabolism · 2026

    Systematic review · 3 results

  22. Efficacy and safety of semaglutide 2.4 mg for weight loss in overweight or obese adults without diabetes: An updated systematic review and meta-analysis including the 2-year STEP 5 trial.

    Qin W · Diabetes, obesity & metabolism · 2024

    Systematic review · 14 results

  23. Effect of semaglutide versus other glucagon-like peptide-1 receptor agonists on cardio-metabolic risk factors in patients with type 2 diabetes: A systematic review and meta-analysis of head-to-head, phase 3, randomized controlled trials.

    Patoulias D · Journal of diabetes and its complications · 2023

    Systematic review · 10 results

  24. Potent incretin-based therapy for obesity: A systematic review and meta-analysis of the efficacy of semaglutide and tirzepatide on body weight and waist circumference, and safety.

    Müllertz ALO · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2024

    Systematic review · 6 results

  25. Efficacy of subcutaneous semaglutide compared to placebo for weight loss in obese, non-diabetic adults: a systematic review & meta-analysis.

    Arastu N · International journal of clinical pharmacy · 2022

    Systematic review · 1 result

  26. Efficacy and safety of once-weekly subcutaneous semaglutide 2.4 mg for the management of overweight or obesity in Asian populations: A systematic review, meta-analysis and meta-regression of randomised trials.

    Zufry H · Diabetes, obesity & metabolism · 2025

    Systematic review · 8 results

  27. A systematic review of the effect of semaglutide on lean mass: insights from clinical trials.

    Bikou A · Expert opinion on pharmacotherapy · 2024

    Systematic review · 4 results

  28. Cardiovascular Effects of Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction: A Systematic Review and Meta-Analysis.

    Sobral MVS · American journal of cardiovascular drugs : drugs, devices, and other interventions · 2025

    Systematic review · 4 results

  29. Impact of semaglutide exposure on fetal and neonatal outcomes in pregnant women: a systematic review.

    Mandal L · European journal of obstetrics, gynecology, and reproductive biology · 2026

    Systematic review · 10 results

  30. Meta-analysis of the effects of semaglutide on body mass index (BMI) and blood lipid levels in polycystic ovary syndrome patients.

    Chen W · Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology · 2025

    Systematic review · 6 results

  31. Efficacy and safety of semaglutide in non-alcoholic fatty liver disease.

    Zhu K · World journal of gastroenterology · 2023

    Systematic review · 13 results

  32. Long-Term Safety and Renal Outcomes of Semaglutide in Non-Diabetic Obesity with Chronic Kidney Disease or Hypertension: A Systematic Review and Meta-Analysis.

    Elganyny MKE · La Clinica terapeutica · 2026

    Systematic review · 3 results

  33. Impact of Semaglutide Administration on Weight Loss After Bariatric Surgery: A Meta-Analysis.

    Jamialahamdi T · Obesity surgery · 2025

    Systematic review · 2 results

  34. Glucagon-Like Peptide-1 Receptor Agonists in Post-bariatric Surgery Patients: A Systematic Review and Meta-analysis.

    Dutta D · Obesity surgery · 2024

    Systematic review · 8 results

  35. Pharmacological interventions for the management of children and adolescents living with obesity-An update of a Cochrane systematic review with meta-analyses.

    Torbahn G · Pediatric obesity · 2024

    Systematic review · 7 results

  36. Cost-effectiveness of Semaglutide Compared With Other Glucose-Lowering Medications in Treating Type 2 Diabetes: A Comprehensive Systematic Review and Meta-analysis.

    Liu Z · Diabetes care · 2025

    Systematic review · 5 results

  37. A systematic review of semaglutide-associated kidney injury case reports.

    Xiu X · Frontiers in medicine · 2026

    Systematic review · 4 results

  38. Wernicke's Encephalopathy Following Semaglutide Treatment for Obesity: A Systematic PRISMA Review of Case-Based Evidence.

    Bidesie J · Obesity (Silver Spring, Md.) · 2026

    Systematic review · 4 results

  39. Comparative effectiveness of GLP-1 receptor agonists on glycaemic control, body weight, and lipid profile for type 2 diabetes: systematic review and network meta-analysis.

    Yao H · BMJ (Clinical research ed.) · 2024

    Systematic review · 11 results

  40. Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.

    Tsapas A · Annals of internal medicine · 2020

    Systematic review · 6 results

  41. Anti-diabetic drugs and weight loss in patients with type 2 diabetes.

    Lazzaroni E · Pharmacological research · 2021

    Systematic review · 3 results

  42. Effect of glucagon-like peptide-1 receptor agonists on body weight in adults with obesity without diabetes mellitus-a systematic review and meta-analysis of randomized control trials.

    Iqbal J · Obesity reviews : an official journal of the International Association for the Study of Obesity · 2022

    Systematic review · 28 results

  43. Comparative efficacy of glucose-lowering medications on body weight and blood pressure in patients with type 2 diabetes: A systematic review and network meta-analysis.

    Tsapas A · Diabetes, obesity & metabolism · 2021

    Systematic review · 7 results

  44. Effect of glucagon-like peptide-1 receptor agonists and co-agonists on body composition: Systematic review and network meta-analysis.

    Karakasis P · Metabolism: clinical and experimental · 2025

    Systematic review · 23 results

  45. Pharmacotherapy for adults with overweight and obesity: a systematic review and network meta-analysis of randomised controlled trials.

    Shi Q · Lancet (London, England) · 2024

    Systematic review · 5 results

  46. Adverse drug reactions of GLP-1 agonists: A systematic review of case reports.

    Shetty R · Diabetes & metabolic syndrome · 2022

    Systematic review · 30 results

  47. Association of glucose-lowering medications with cardiovascular outcomes: an umbrella review and evidence map.

    Zhu J · The lancet. Diabetes & endocrinology · 2020

    Systematic review · 13 results

  48. Effects of Anti-Diabetic Drugs on Fracture Risk: A Systematic Review and Network Meta-Analysis.

    Zhang YS · Frontiers in endocrinology · 2021

    Systematic review · 2 results

  49. Comparison of pharmacological therapies in metabolic dysfunction-associated steatohepatitis for fibrosis regression and MASH resolution: Systematic review and network meta-analysis.

    Souza M · Hepatology (Baltimore, Md.) · 2025

    Systematic review · 9 results

  50. Subcutaneously administered tirzepatide vs semaglutide for adults with type 2 diabetes: a systematic review and network meta-analysis of randomised controlled trials.

    Karagiannis T · Diabetologia · 2024

    Systematic review · 18 results

How PepBank reports evidence